AI Article Synopsis

Article Abstract

Background: The Poincaré plot (PCP) is a valuable tool for describing glucose variability (GV) from continuous glucose monitoring (CGM) but remains only visual and qualitative. The aim of this work was to validate metrics for the geometry of the PCP in type 1 diabetes and to apply them to the study of a series of patients switching to continuous subcutaneous insulin infusion (CSII).

Patients And Methods: We reviewed the CGM profiles of 44 patients with type 1 diabetes. A subgroup (n=13) used CGM before and after 6 months on CSII. Additionally, we prospectively collected seven recordings from healthy controls. The new PCP metrics were correlated with hypoglycemia and classical GV indices and were compared between groups.

Results: SDs related to the PCP fitting ellipse (SD1, SD2) and area and shape of the fitting ellipse (SFE) were all higher in diabetes patients than in the controls and decreased significantly on CSII. SD1 represented short-term GV and was equivalent to continuous overlapping net glycemic action (CONGA). SD2 represented long-term GV and correlated with the SD of glucose levels (r ≥ 0.98), mean of daily differences (r ≥ 0.91), and mean amplitude of glycemic excursions (r ≥ 0.88). SFE correlated positively with CONGA at 1 h but not with the other indices and was inversely correlated with hypoglycemic episodes (Spearman's ρ=-0.42), independently of the coefficient of variation and the Low Blood Glucose Index in a multivariate analysis (partial r=-0.34).

Conclusions: PCP metrics are correlated with known GV indices and may be used for the study of CGM recording series in type 1 diabetes. SFE is a new risk marker for hypoglycemia.

Download full-text PDF

Source
http://dx.doi.org/10.1089/dia.2013.0241DOI Listing

Publication Analysis

Top Keywords

type diabetes
16
poincaré plot
8
glucose variability
8
variability continuous
8
continuous glucose
8
glucose monitoring
8
risk marker
8
marker hypoglycemia
8
diabetes patients
8
patients switching
8

Similar Publications

Background: Thyroid Hormones (THs) critically impact human cancer. Although endowed with both tumor-promoting and inhibiting effects in different cancer types, excess of THs has been linked to enhanced tumor growth and progression. Breast cancer depends on the interaction between bulk tumor cells and the surrounding microenvironment in which mesenchymal stem cells (MSCs) exert powerful pro-tumorigenic activities.

View Article and Find Full Text PDF

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are emerging as an important class of drugs in the management of Type 2 Diabetes Mellitus (T2DM) and obesity. There are rising concerns of pulmonary aspiration with these medications due to drug-induced gastroparesis. While definitive association is uncertain, it is essential to be prudent and manage these patients as per the current evidence and recommendations.

View Article and Find Full Text PDF

Diabetes is a chronic lifelong condition that requires consistent self-care and daily lifestyle adjustments. Effective disease management involves regular blood glucose monitoring and ongoing nursing support. Inadequate education and poor self-management are key factors contributing to increased mortality among diabetic individuals.

View Article and Find Full Text PDF

Management of SGLT-2 Inhibitors in the Perioperative Period: Withhold or Continue?

Br J Hosp Med (Lond)

January 2025

Department of Anaesthesia, Northumbria Healthcare NHS Foundation Trust, Newcastle-Upon-Tyne, UK.

Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are commonly prescribed in diabetes mellitus and increasingly for cardiorenal protection. They carry the risk of euglycaemic diabetic ketoacidosis (eDKA). Guidelines around the perioperative handling of these medications are limited and some evidence suggests that withholding them can lead to more surgical complications and poorer glycaemic control.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!